SG11201705312PA - Composition containing nucleic acid molecule stably - Google Patents

Composition containing nucleic acid molecule stably

Info

Publication number
SG11201705312PA
SG11201705312PA SG11201705312PA SG11201705312PA SG11201705312PA SG 11201705312P A SG11201705312P A SG 11201705312PA SG 11201705312P A SG11201705312P A SG 11201705312PA SG 11201705312P A SG11201705312P A SG 11201705312PA SG 11201705312P A SG11201705312P A SG 11201705312PA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid molecule
composition containing
containing nucleic
molecule stably
Prior art date
Application number
SG11201705312PA
Inventor
Taimu Yamada
Hidekazu Toyofuku
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of SG11201705312PA publication Critical patent/SG11201705312PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705312PA 2014-12-29 2015-10-30 Composition containing nucleic acid molecule stably SG11201705312PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014267087 2014-12-29
JP2015081298 2015-04-10
PCT/JP2015/080849 WO2016108264A1 (en) 2014-12-29 2015-10-30 Composition containing nucleic acid molecule stably

Publications (1)

Publication Number Publication Date
SG11201705312PA true SG11201705312PA (en) 2017-07-28

Family

ID=56284418

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705312PA SG11201705312PA (en) 2014-12-29 2015-10-30 Composition containing nucleic acid molecule stably

Country Status (14)

Country Link
US (2) US20180036409A1 (en)
EP (1) EP3241903A4 (en)
JP (2) JP6462723B2 (en)
KR (2) KR102585112B1 (en)
CN (1) CN107208094A (en)
AU (2) AU2015373071B2 (en)
BR (1) BR112017014090A2 (en)
CA (1) CA2971830A1 (en)
HK (1) HK1244030A1 (en)
IL (1) IL252905B (en)
MX (1) MX2017008730A (en)
RU (1) RU2723032C2 (en)
SG (1) SG11201705312PA (en)
WO (1) WO2016108264A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073767A1 (en) 2015-10-30 2017-05-04 株式会社ボナック COMPOSITION STABLY CONTAINING SINGLE-STRANDED NUCLEIC ACID MOLECULE THAT SUPPRESSES EXPRESSION OF TGF-β1 GENE
EP3532086A1 (en) * 2016-10-27 2019-09-04 Selexel Novel bispecific double-stranded oligonucleotide for treating cancer
FR3058061A1 (en) * 2016-10-27 2018-05-04 Selexel NEW USE OF DOUBLE STRAND OLIGONUCLEOTIDES
CN106857502A (en) * 2017-03-03 2017-06-20 湖北新纵科病毒疾病工程技术有限公司 A kind of the Sample storage liquid and store method that prevent RNA from degrading
KR20200033927A (en) 2017-07-28 2020-03-30 교린 세이야꾸 가부시키 가이샤 Treatment for fibrosis
US20210188895A1 (en) 2017-10-13 2021-06-24 Bonac Corporation Single-stranded nucleic acid molecule, and production method therefor
CN109402127B (en) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 Group of high-affinity nucleic acid aptamers capable of being specifically bound with connective tissue growth factor and application of high-affinity nucleic acid aptamers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102724A (en) 1981-12-15 1983-06-18 Mitsubishi Chem Ind Ltd Slip resistant polyolefin molded product
CA2089666C (en) 1990-08-16 2003-01-07 Kevin P. Anderson Oligonucleotides for modulating the effects of cytomegalovirus infections
CA2252565C (en) * 1996-04-26 2010-11-23 David B. Volkin Dna vaccine formulations
ES2259188T3 (en) 1996-10-25 2006-09-16 Gilead Sciences, Inc. NUCLEIC ACID BINDING COMPLEXES OF VASCULAR ENDOTELIAL GROWTH FACTOR (VEGF).
ZA99493B (en) * 1998-01-30 1999-07-22 Akzo Nobel Nv Method for the isolation of nucleic acid.
BR9908754A (en) * 1998-03-13 2000-11-28 American Home Prod Lyophilized and liquid polynucleotide and pharmaceutical compositions, processes for treating a mammalian patient and for preparing a lyophilized polynucleotide composition, lyophilized polynucleotide product, and, process for lyophilizing a polynucleotide composition
DE19836559A1 (en) * 1998-08-12 2000-03-23 Antigen Gmbh Blood collection vessel
KR100718191B1 (en) * 1999-12-02 2007-05-15 하이모 가부시키가이샤 Precast polyacrylamide electrophoresis gel, production method thereof and electrophoresis using the gel
JP3967516B2 (en) * 2000-02-29 2007-08-29 ハイモ株式会社 DNA electrophoresis
DE10006662A1 (en) * 2000-02-15 2001-08-23 Antigen Produktions Gmbh Sample vessel for stabilizing and isolating nucleic acid, contains a lytic solution that stabilizes nucleic acid and a solid phase that binds it, especially for sampling whole blood
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2004110980A1 (en) * 2003-06-18 2004-12-23 Biolab Ltd. Sphingolipids' polyalkylamines conjugates
KR101094032B1 (en) * 2003-09-17 2011-12-19 센텔리옹 에스아에스 Method of preparation of pharmaceutically grade plasmid dna
EP1791945A1 (en) * 2004-09-17 2007-06-06 Centelion Stable liquid formulations of plasmid dna
DE102005023170A1 (en) * 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
CA3044134A1 (en) * 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
JP5608998B2 (en) * 2009-03-31 2014-10-22 東洋紡株式会社 Nucleic acid amplification detection reagent kit with excellent storage stability
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2012099755A1 (en) * 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
AU2012330819B2 (en) * 2011-11-04 2017-08-31 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
RS58985B1 (en) * 2012-03-15 2019-08-30 Acraf Glycogen-based cationic polymers
CA2872901A1 (en) * 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
CA2888286C (en) * 2013-03-06 2020-03-24 Biomics Biotechnologies Co., Ltd. Liposome formulation, its preparation and application

Also Published As

Publication number Publication date
EP3241903A1 (en) 2017-11-08
CA2971830A1 (en) 2016-07-07
AU2022204391A1 (en) 2022-07-14
AU2015373071A1 (en) 2017-07-13
KR20170094797A (en) 2017-08-21
RU2723032C2 (en) 2020-06-08
KR102585112B1 (en) 2023-10-10
MX2017008730A (en) 2017-11-17
EP3241903A4 (en) 2018-07-04
JP2019077696A (en) 2019-05-23
RU2017126568A (en) 2019-01-31
AU2015373071B2 (en) 2022-03-31
JPWO2016108264A1 (en) 2017-08-31
BR112017014090A2 (en) 2018-03-06
US20180036409A1 (en) 2018-02-08
CN107208094A (en) 2017-09-26
WO2016108264A1 (en) 2016-07-07
IL252905B (en) 2020-09-30
JP6808710B2 (en) 2021-01-06
US20240016937A1 (en) 2024-01-18
IL252905A0 (en) 2017-08-31
RU2017126568A3 (en) 2019-05-20
KR20220035404A (en) 2022-03-22
HK1244030A1 (en) 2018-07-27
JP6462723B2 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
SG11201911430PA (en) Novel nucleic acid molecules
HRP20190235T1 (en) Antisense nucleic acid
IL252556A0 (en) Nucleic acid constructs for genome editing
SG11201610168YA (en) Nucleic acid synthesis techniques
SG11201704681QA (en) Artificial nucleic acid molecules
ZA201702211B (en) Nucleic acid purification cartridge
PT3159409T (en) Antisense nucleic acid
HK1243958A1 (en) Nucleic acid construct
GB201507119D0 (en) Nucleic Acid Construct
HK1244021A1 (en) Nucleic acid construct
HK1244030A1 (en) Composition containing nucleic acid molecule stably
PT3094731T (en) Saccharide-modified nucleic acid molecules
GB201421379D0 (en) Molecule
GB201507111D0 (en) Nucleic acid construct
GB201507115D0 (en) Nucleic Acid Construct
IL246655B (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
GB201403216D0 (en) Nucleic acid sample preparation
GB201413318D0 (en) Nucleic acid sample preparation
GB201506669D0 (en) Nucleic acid sample enrichment
GB201415674D0 (en) Nucleic acid analysis
GB201414451D0 (en) Hybridisation column for nucleic acid enrichment
HK1231403A1 (en) Nucleic acid capable of inhibiting expression of beta2gpi 2gpi
EP3351251A4 (en) Nucleic acid molecule
GB2553907B (en) Nucleic acid analyzer
HK1244035A1 (en) Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression